CRISPR/Cas9 genome editing of CCR5 combined with C46 HIV-1 fusion inhibitor for cellular resistant to R5 and X4 tropic HIV-1

Abstract Hematopoietic stem-cell (HSC) transplantation using a donor with a homozygous mutation in the HIV co-receptor CCR5 (CCR5Δ32/Δ32) holds great promise as a cure for HIV-1. Previously, there were three patients that had been reported to be completely cured from HIV infection by this approach....

Descripción completa

Detalles Bibliográficos

Autores principales:	Wannisa Khamaikawin, Chonticha Saisawang, Boonrat Tassaneetrithep, Kanit Bhukhai, Phetcharat Phanthong, Suparerk Borwornpinyo, Angsana Phuphuakrat, Ekawat Pasomsub, Sujittra Chaisavaneeyakorn, Usanarat Anurathapan, Nopporn Apiwattanakul, Suradej Hongeng
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Nature Portfolio 2024-05-01
Colección:	Scientific Reports
Materias:	CCR5 CRISPR/Cas9 C46 HIV-1 fusion inhibitor HIV-1 gene therapy
Acceso en línea:	https://doi.org/10.1038/s41598-024-61626-x
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!